Molecular epidemiology and viral load of HCV in different regions of Punjab, Pakistan

Virology Journal

Volumn 11, Issue 1, 2014, Pages

  Afridi, Suliman Qadir ^a   Ali, Muhammad Muddassir ^a   Awan, Furqan ^a   Zahid, Muhammad Nauman ^a   Afridi, Irfan Qadir ^b   Afridi, Sara Qadir ^b   Yaqub, Tahir ^a  

^a UVAS   (Pakistan)

^b Ideal Laboratories   (Pakistan)

Author keywords

Genotype 3a; Hepatitis C virus; Pakistan; Viral load

Indexed keywords

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VARIATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; PAKISTAN; POLYMERASE CHAIN REACTION; PREVALENCE; VIRAL LOAD; YOUNG ADULT;

EID: 84893711400     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-11-24     Document Type: Article

References (20)

1. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization, International Committee on Virus Taxonomy. Robertson B, Myers G, Howard C, Brettin T, Bukh J, Gaschen B, Gojobori T, Maertens G, Mizokami M, Nainan O, et al. Arch Virol 1998 143 2493 2503 10.1007/s007050050479 9930205 (Pubitemid 29022697)
2. Internal ribosome entry site within hepatitis C virus RNA. Tsukiyama-Kohara K, Iisuka N, Kohara M, Nomoto A, J Virol 1992 66 1476 1483 1310759
3. Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Hnatyszyn HJ, Antivir Ther 2005 10 1 11 15751759 (Pubitemid 40767627)
4. Variability of hepatitis C virus. Simmonds P, Hepatology 1995 21 570 583 10.1002/hep.1840210243 7531173
5. Course and outcome of hepatitis C. Hoofnagle JH, Hepatology 2002 36 21 S29 12407573
6. Distribution of HCV genotypes and HCV RNA viral load in different regions of Mexico. Jimenez-Mendez R, Uribe-Salas F, Lopez-Guillen P, Cisneros-Garza L, Castaneda-Hernandez G, Ann Hepatol 2010 9 33 39
7. Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. Idrees M, Riazuddin S, BMC Infect Dis 2008 8 69 10.1186/1471-2334-8-69 18498666 (Pubitemid 351803135)
8. Investigating the origin and spread of hepatitis C virus genotype 5a. Verbeeck J, Maes P, Lemey P, Pybus OG, Wollants E, Song E, Nevens F, Fevery J, Delport W, Van der Merwe S, Van Ranst M, J Virol 2006 80 4220 4226 10.1128/JVI.80.9.4220-4226.2006 16611881
9. Hepatitis C virus genetic variability: pathogenic and clinical implication. Pawlotsky JM, Clin Liver Dis 2003 7 45 66 10.1016/S1089-3261(02) 00065-X 12691458 (Pubitemid 36350751)
10. Determination of HCV genotypes and viral loads in chronic HCV infected patients of Hazara Pakistan. Ali A, Nisar M, Ahmad H, Saif N, Idrees M, Bajwa MA, Virol J 2011 8 466 10.1186/1743-422X-8-466 21982599
11. Prevalence of HCV genotypes in district Mardan. Afridi SQ, Zahid MN, Shabbir MZ, Hussain Z, Mukhtar N, Tipu MY, Akhtar F, Yaqub T, Virol J 2013 10 90 10.1186/1743-422X-10-90 23514695
12. Hepatitis C virus genotypes in Pakistan: a systemic review. Attaullah S, Khan S, Ali I, Virol J 2011 8 433 10.1186/1743-422X-8-433 21902822
13. Epidemiology of hepatitis C virus infection in Pakistan. Raja NS, Janjua KA, J Microbiol Immunol Infect 2008 41 4 8 18327420 (Pubitemid 351792115)
14. Epidemiological manifestations of hepatitis C virus genotypes and its association with potential risk factors among Libyan patients. Elasifer HA, Agnnyia YM, Al-Alagi BA, Daw MA, Virol J 2010 7 317 10.1186/1743-422X-7-317 21073743
15. HCV genotype distribution and possible transmission risks in Lahore, Pakistan. Ahmad W, Ijaz B, Javed FT, Jahan S, Shahid I, Khan FM, Hassan S, World J Gastroenterol 2010 16 4321 4328 10.3748/wjg.v16.i34.4321 20818816
16. Epidemiology of hepatitis C virus (HCV) infection. Sy T, Jamal MM, Int J Med Sci 2006 3 41 46 16614741
17. HCV 3 in Pakistan: does it offer more hope for cure and control. Mujeeb SA, J Pak Med Assoc 2002 52 191 12174488
18. Comparison of hepatitis C viral loads in patients with or without coinfection with different genotypes. Schijman A, Colina R, Mukomolov S, Kalinina O, García L, Broor S, Bhupatiraju A, Karayiannis K, Khan B, Mogdasy C, Cristina J, Clin Diagn Lab Immunol 2004 11 433 435 15014001 (Pubitemid 38380831)
19. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, Raknerud N, Bell H, Hepatology 2004 40 1260 1265 10.1002/hep.20467 15558712 (Pubitemid 39656999)
20. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, Bergk A, Bernsmeier C, Haussinger D, Herrmann E, Zeuzem S, Gastroenterology 2005 129 522 527 16083709 (Pubitemid 41096640)